杂合PCSK1变异对肥胖的贡献及精准医学意义:一项病例对照研究
该病例对照研究对RaDiO研究中9320名参与者测序PCSK1全部13个编码外显子,检出65个罕见杂合变异,其中15个错义变异导致PC1/3完全功能丧失。携带完全功能丧失或无义PCSK1变异与肥胖显著相关(7例携带者中6例[86%] vs 4395例非携带者中1518例[35%];OR 9.3 [95% CI 1.5-177.4];p=0.014),且携带者BMI更高(32.0 kg/m2 [SD 9.3] vs 27.3 kg/m2 [6.5];平均效应π 6.94 [SE 1.95];p=0.00029)。部分或中性效应变异簇与肥胖、超重及BMI无关。
要点
- 携带杂合无义或完全功能丧失PCSK1变异者肥胖风险显著升高(OR 9.3,95% CI 1.5-177.4)。
- 携带者BMI显著高于非携带者(32.0 kg/m2 vs 27.3 kg/m2,p=0.00029)。
- 部分或中性效应PCSK1变异簇与肥胖、超重及BMI无关。
核心结论
- 仅携带杂合无义或完全功能丧失PCSK1变异者导致单基因肥胖,可能符合setmelanotide治疗条件。
- 计算机模拟试验无法准确检测这些变异,提示需体外试验确定变异致病性以用于遗传诊断和精准医学。
研究设计与样本
- 病例对照研究纳入RaDiO研究中1995年1月1日至2000年12月31日招募的三个社区队列和一个医院队列的超重/肥胖(病例)或健康体重(对照)参与者。
- 对9320名参与者(7260名成人、2060名儿童和青少年)测序PCSK1全部13个编码外显子。
- 对罕见错义变异进行体外功能评估,并用机器学习确定致病性聚类,用调整混合效应评分检验评估各变异簇对肥胖的影响。
主要发现
- 检出65个罕见杂合PCSK1变异,包括4个无义变异和61个错义变异,后者体外分析后按酶活性分为A-E五组。
- 与野生型相比,15个错义变异导致PC1/3完全功能丧失(A组;参考),REVEL导致15个(25%)假阳性和4个(7%)假阴性。
- 携带完全功能丧失或无义PCSK1变异与肥胖显著相关(7例携带者中6例[86%] vs 4395例非携带者中1518例[35%];OR 9.3 [95% CI 1.5-177.4];p=0.014)。
- 携带者BMI高于非携带者(32.0 kg/m2 [SD 9.3] vs 27.3 kg/m2 [6.5];平均效应π 6.94 [SE 1.95];p=0.00029)。
- 部分或中性效应PCSK1变异簇与肥胖、超重及BMI无关。
关键数值与推荐
- 成人健康体重定义为BMI低于25.0 kg/m2,超重为25.0-29.9 kg/m2,肥胖为30.0 kg/m2或更高。
- 2型糖尿病定义为空腹血糖7.0 mmol/L或更高或使用降糖治疗(或两者兼有),且胰岛或胰岛素自身抗体阴性。
- 携带完全功能丧失或无义PCSK1变异与肥胖的OR为9.3(95% CI 1.5-177.4;p=0.014)。
- 携带者BMI为32.0 kg/m2(SD 9.3),非携带者为27.3 kg/m2(SD 6.5);平均效应π 6.94(SE 1.95;p=0.00029)。
临床怎么用
- 作者认为仅携带杂合无义或完全功能丧失PCSK1变异者导致单基因肥胖,可能符合setmelanotide治疗条件。
- 作者认为计算机模拟试验无法准确检测这些变异,提示需体外试验确定变异致病性以用于遗传诊断和精准医学。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rare biallelic pathogenic mutations in PCSK1 (encoding proprotein convertase subtilisin/kexin type 1 [PC1/3]) cause early-onset obesity associated with various endocrinopathies. Setmelanotide has been approved for carriers of these biallelic mutations in the past 3 years. We aimed to perform a large-scale functional genomic study focusing on rare heterozygous variants of PCSK1 to decipher their putative impact on obesity risk. METHODS: This case-control study included all participants with overweight and obesity (ie, cases) or healthy weight (ie, controls) from the RaDiO study of three community-based and one hospital-based cohort in France recruited between Jan 1, 1995, and Dec 31, 2000. In adults older than 18 years, healthy weight was defined as BMI of less than 25·0 kg/m2, overweight as 25·0-29·9 kg/m2, and obesity as 30·0 kg/m2 or higher. Participants with type 2 diabetes had fasting glucose of 7·0 mmol/L or higher or used treatment for hyperglycaemia (or both) and were negative for islet or insulin autoantibodies. Functional assessment of rare missense variants of PCSK1 was performed. Pathogenicity clusters of variants were determined with machine learning. The effect of each cluster of PCSK1 variants on obesity was assessed using the adjusted mixed-effects score test. FINDINGS: All 13 coding exons of PCSK1 were sequenced in 9320 participants (including 7260 adults and 2060 children and adolescents) recruited from the RaDiO study. We detected 65 rare heterozygous PCSK1 variants, including four null variants and 61 missense variants that were analysed in vitro and clustered into five groups (A-E), according to enzymatic activity. Compared with the wild-type, 15 missense variants led to complete PC1/3 loss of function (group A; reference) and rare exome variant ensemble learner (REVEL) led to 15 (25%) false positives and four (7%) false negatives. Carrying complete loss-of-function or null PCSK1 variants was significantly associated with obesity (six [86%] of seven carriers vs 1518 [35%] of 4395 non-carriers; OR 9·3 [95% CI 1·5-177·4]; p=0·014) and higher BMI (32·0 kg/m2 [SD 9·3] in carriers vs 27·3 kg/m2 [6·5] in non-carriers; mean effect π 6·94 [SE 1·95]; p=0·00029). Clusters of PCSK1 variants with partial or neutral effect on PC1/3 activity did not have an effect on obesity or overweight and on BMI. INTERPRETATION: Only carriers of heterozygous, null, or complete loss-of-function PCSK1 variants cause monogenic obesity and, therefore, might be eligible for setmelanotide. In silico tests were unable to accurately detect these variants, which suggests that in vitro assays are necessary to determine the variant pathogenicity for genetic diagnosis and precision medicine purposes. FUNDING: Agence Nationale de la Recherche, European Research Council, National Center for Precision Diabetic Medicine, European Regional Development Fund, Hauts-de-France Regional Council, and the European Metropolis of Lille.
引用
- Folon L, Baron M, Toussaint B, et al. Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study. Lancet Diabetes Endocrinol. 2023. PMID: 36822744. doi:10.1016/S2213-8587(22)00392-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。